Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+)

Reviewer: Walter Sall, MD
OncoLink
Ultima Vez Modificado: 15 de mayo del 2005

Translation for this article does not exist

Blogs

Smoothies for All Occasions
by OncoLink Editorial Team
May 24, 2016